関連する実験動画
Updated: Feb 12, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
タンパク質製剤の開発可能性評価のためのデータ駆動型および物理ベースモデルを組み合わせた新しいインシリコプラットフォーム
Andrea Arsiccio1, Kristian Le Vay1, Andre Sao Pedro1
1Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.
Abstract:
The development of novel therapeutic proteins is accompanied by huge financial and time investments. Advancing molecules through drug product development without proper scrutiny often leads to costly failures. In some cases, such failures are related to the inherent instability of the candidate molecule, and the difficulty of minimizing these instabilities by selecting a suitable formulation. Early characterization of a protein drug candidate's formulation developability is therefore crucial to reduce the risk. A comprehensive in vitro assessment is often constrained by the scarcity of drug substance material available in early stages of development, raising the interest in simulations and computational models. Currently, only very few in silico methods focusing on formulation development and assessing a protein drug candidate's formulation developability are available. To address this problem, we present a novel in silico platform based on data driven and physics-based models that combines computational techniques spanning different areas, including structure prediction, bioinformatics, machine learning and molecular dynamics calculations. The platform only requires the primary sequence of a therapeutic protein as input, thus eliminating the need for physical material. We describe the computational tools that are part of the platform, and show how they can be used to identify liabilities and outlying properties of the protein drug candidate, evaluate high concentration suitability, screen the effect of formulation conditions on self-interaction propensity, and suggest formulation corridors. We additionally present two case studies that illustrate potential applications of the developed platform to real-world scenarios and prove its experimental validation.
関連する概念動画
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Physical Assessment of the Respiratory Tract II: Inspection
Chest Configuration
The chest configuration...
Physical Assessment of the Respiratory Tract II: Palpation
Thoracic Palpation
Thoracic palpation detects tenderness, masses, lesions, respiratory excursions, and vocal fremitus. The nurse assesses...
Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Physical Assessment of the Respiratory Tract I: Health History
Subjective Data
Subjective data provides vital information about the patient's health history and symptoms. This data is typically collected through interviews in which patients describe their experiences, symptoms, and concerns.
Health history and...

